Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies

Arthritis Care and Research

Volumn 66, Issue 5, 2014, Pages 732-740

  Huber, Adam M ^a   Mamyrova, Gulnara ^b   Lachenbruch, Peter A ^c   Lee, Julia A ^c   Katz, James D ^b   Targoff, Ira N ^d   Miller, Frederick W ^c   Rider, Lisa G ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; SYNTHETASE AUTOANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONNECTIVE TISSUE DISEASE ASSOCIATED MYOSITIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE; JUVENILE DERMATOMYOSITIS; JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHY; JUVENILE POLYMYOSITIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYOSITIS; ONSET AGE; POLYMYOSITIS; PROPORTIONAL HAZARDS MODEL; RANDOM FOREST; RANDOM SURVIVAL FOREST; RAYNAUD PHENOMENON; RISK FACTOR; STANDARDIZED MORTALITY RATIO; UNITED STATES; UNIVARIATE ANALYSIS; WEIGHT REDUCTION;

ADOLESCENT; ADULT; CHILD; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYOSITIS; RISK FACTORS; YOUNG ADULT;

EID: 84899094540     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22212     Document Type: Article

References (31)

1. Feldman BM, Rider LG, Reed AM, Pachman LM,. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371: 2201-12. (Pubitemid 351890413)
2. Shah M, Mamyrova G, Targoff I, Huber AM, Malley JD, Rice M, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92: 25-41.
3. Rider LG, Shah M, Mamyrova G, Huber AM, Malley JD, Rice M, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92: 223-43.
4. Airio A, Kautiainen H, Hakala M,. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25: 234-9. (Pubitemid 43372323)
5. Bronner IM, van der Meulen MF, de Visser M, Kalmijn S, van Venrooij WJ, Voskuyl AE, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006; 65: 1456-61. (Pubitemid 44629122)
6. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G,. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004; 83: 35-42. (Pubitemid 38124854)
7. Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011; 165: 1273-9.
8. Limaye V, Hakendorf P, Woodman RJ, Blumbergs P, Roberts-Thomson P,. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J 2012; 42: 191-8.
9. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012; 41: 890-9.
10. Shu XM, Lu X, Xie Y, Wang GC,. Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China. BMC Neurol 2011; 11: 143.
11. Torres C, Belmonte R, Carmona L, Gomez-Reino FJ, Galindo M, Ramos B, et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006; 39: 205-15. (Pubitemid 43879033)
12. Woo JH, Kim YJ, Kim JJ, Choi CB, Sung YK, Kim TH, et al. Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease. Mod Rheumatol 2013; 23: 503-8.
13. Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol 2011; 38: 1636-43.
14. Lundberg IE, Forbess CJ,. Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 2008; 26 Suppl: S109-14.
15. Bitnum S, Daeschner C Jr, Travis LB, Dodge WF, Hopps HC,. Dermatomyositis. J Pediatr 1964; 64: 101-31.
16. Huber AM,. Idiopathic inflammatory myopathies in childhood: current concepts. Pediatr Clin North Am 2012; 59: 365-80.
17. Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010; 62: 599-608.
18. Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N, et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 2011; 29: 117-24.
19. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45: 1255-60. (Pubitemid 44542066)
20. Bohan A, Peter JB,. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
21. Arias E, Curtin LR, Wei R, Anderson RN,. US decennial life tables for 1999-2001, United States life tables. Natl Vital Stat Rep 2008; 57: 1-36.
22. Therneau TM, Grambsch PM,. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2010.
23. Ishwaran H, Kogalur UB, Blackstone E, Lauer MS,. Random survival forests. Ann Appl Stat 2008; 2: 841-60.
24. Ishwaran H, Kogalur UB,. Random survival forests for R. R News 2007; 7: 25-31.
25. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA,. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134: 3167-75.
26. Austin PC, Lee DS, Steyerberg EW, Tu JV,. Regression trees for predicting mortality in patients with cardiovascular disease: what improvement is achieved by using ensemble-based methods? Biom J 2012; 54: 657-73.
27. Hsich E, Gorodeski EZ, Blackstone EH, Ishwaran H, Lauer MS,. Identifying important risk factors for survival in patient with systolic heart failure using random survival forests. Circ Cardiovasc Qual Outcomes 2011; 4: 39-45.
28. Ward MM, Pajevic S, Dreyfuss J, Malley JD,. Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. Arthritis Rheum 2006; 55: 74-80. (Pubitemid 43235130)
29. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC,. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 2012; 14: R22.
30. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360-74.
31. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV,. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50: 209-15. (Pubitemid 38084306)